



LKT Laboratories, Inc.

GDC-0941

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID G124082

CAS No. 957054-30-7

Chemical Name

Synonym GNE-0941, Pictilisib, Pictrelisib, RG7321

Formula $C_{23}H_{27}N_7O_3S_2$

Formula Wt. 513.64

Melting Point


Purity $\geq 98\%$

Solubility

Store Temp -20°C

Ship Temp Ambient

Description GDC-0941 is a pan-PI3K inhibitor. When combined with paclitaxel, GDC-0941 exhibits antitumor activity in patients with locally recurrent or metastatic breast cancer. It also increases apoptosis in several cell lines of uveal melanoma in combination with the mTOR inhibitor everolimus.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
G124082	5 mg	\$77.80
G124082	25 mg	\$175.20
G124082	100 mg	\$486.80

References Folkes A., Ahmadi K., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. *J Med Chem.* 51(18):5522-32 (2008). PMID: 18754654.

Schoffski P., Cresta S., et al. A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. *Breast Cancer Res.* 20(1):109 (2018). PMID: 30185228.

Amirouchene-Angelozzi N., Frisch-Dit-Leitz E., et al. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. *Oncotarget.* 7(17):23633-46 (2016). PMID: 26988753.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.